1. Stage III Hypertension in Patients After mRNA-Based SARS-CoV-2 Vaccination
- Author
-
François Marguet, Maryline Foerster, Patrick James Genoud, Sylvain Meylan, Grégoire Wuerzner, Françoise Livio, and CHUV COVID Vaccination Center
- Subjects
Male ,2019-20 coronavirus outbreak ,COVID-19 Vaccines ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Risk Factors ,Internal Medicine ,Humans ,Psychology ,In patient ,Stage (cooking) ,Adverse effect ,BNT162 Vaccine ,Aged ,Messenger RNA ,SARS-CoV-2 ,Vaccination ,COVID-19 ,Blood Pressure Determination ,Virology ,Causality ,Hypertension ,Female ,Symptom Assessment ,Needs Assessment ,Switzerland ,Blood Pressure Determination/methods ,Blood Pressure Determination/psychology ,COVID-19/epidemiology ,COVID-19/prevention & control ,COVID-19/psychology ,COVID-19 Vaccines/administration & dosage ,COVID-19 Vaccines/adverse effects ,Hypertension/diagnosis ,Hypertension/epidemiology ,Hypertension/etiology ,Switzerland/epidemiology ,Symptom Assessment/methods ,Vaccination/methods ,Vaccination/psychology ,headache ,humans ,hypertension ,vaccines ,vital signs - Published
- 2021